Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorSpyridonidis, Alexandros
dc.contributor.authorLabopin, Myriam
dc.contributor.authorSavani, Bipin
dc.contributor.authorGiebel, Sebastian
dc.contributor.authorBug, Gesine
dc.contributor.authorSchoenland, Stefan
dc.contributor.authorKroeger, Nicolaus
dc.date.accessioned2024-02-04T13:29:44Z
dc.date.available2024-02-04T13:29:44Z
dc.date.issued2023
dc.identifier.issn2572-9241
dc.identifier.urihttps://doi.org/10.1097/HS9.0000000000000812
dc.identifier.urihttp://hdl.handle.net/11446/4737
dc.description.abstractIn this registry-based study, we compared outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with acute lymphoblastic leukemia (ALL) transplanted in first complete remission (CR-1), following conditioning with total body irradiation (TBI) at a standard 12-Gray or at a lower 8-Gray total dose. Patients received fludarabine (flu) as the sole chemotherapy complementing TBI. Eight-Gray TBI/flu was used in 494 patients and 12-Gray TBI/flu in 145 patients. Eighty-eight (23.1%) and 36 (29%) of the patients had Ph-negative B-ALL, 222 (58.3%) and 53 (42.7%) had Ph-positive B-ALL, 71 (18.6%) and 35 (28.2%) T-ALL, respectively (P = 0.008). Patients treated with 8-Gray were older than ones received 12-Gray (median 55.7 versus 40.3 years, P < 0.0001) and were more frequently administered in vivo T-cell depletion (71% versus 40%, P <0.0001). In a multivariate model adjusted for age, type of ALL, and other prognostic factors, leukemia-free survival (primary endpoint) as well as relapse, nonrelapse mortality, overall survival, and GVHD-free, relapse-free survival were not influenced by the TBI dose. These results were confirmed when we focused on patients <55 years of age (median 47 years). Patients with Ph-positive ALL or T-ALL had significantly better survival outcomes than ones with Ph-negative B-ALL, mainly due to significantly fewer relapses. We conclude that 8-Gray TBI is sufficient for adult patients with ALL transplanted in CR-1 with no additional benefit of augmenting the conditioning intensity to 12-Gray.en_US
dc.description.sponsorshipInstitute of Cell Therapy, University Research Center, University of Patrasen_US
dc.description.sponsorshipArticle Publication Charges are funded by the Institute of Cell Therapy, University Research Center, University of Patrasen_US
dc.language.isoengen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofHemasphereen_US
dc.identifier.doi10.1097/HS9.0000000000000812
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleReduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMTen_US
dc.typearticleen_US
dc.departmentDBÜen_US
dc.identifier.issue1en_US
dc.identifier.volume7en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-temp[Spyridonidis, Alexandros] Univ Patras, Bone Marrow Transplantat Unit, Patras, Greece; [Spyridonidis, Alexandros] Univ Patras, Inst Cellular Therapy, Patras, Greece; [Labopin, Myriam; Mohty, Mohamad] Sorbonne Univ, St Antoine Hosp, AP HP, INSERM UMRs 938, Paris, France; [Savani, Bipin] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Giebel, Sebastian] Mar Sklodowska Curie Natl Res Inst Oncol, Gliwice, Poland; [Bug, Gesine] Goethe Univ, Dept Med 2, Hematol, Med Oncol, Frankfurt, Germany; [Schoenland, Stefan] Univ Hosp Heidelberg, Med Dept 5, Heidelberg, Germany; [Kroeger, Nicolaus] Univ Med Ctr, Dept Stem Cell Transplantat, Hamburg, Germany; [Stelljes, Matthias] Univ Munster, Dept Hematol Oncol, Munster, Germany; [Schroeder, Thomas] Univ Hosp, Dept Bone Marrow Transplantat, Essen, Germany; [McDonald, Andrew] Netcare Pretoria East Hosp, Alberts Cellular Therapy, Pretoria, South Africa; [Blau, Igor-Wolfgang] Charite Univ Med Berlin, Berlin, Germany; [Bornhaeuser, Martin] Tech Univ Dresden, Univ Hosp, Dresden, Germany; [Rovira, Montse] Josep Carreras Inst, Inst Hematol & Oncol, Hematol Dept, BMT Unit, Barcelona, Spain; [Bethge, Wolfgang] Univ Hosp Tuebingen, Med Ctr, Dept Hematol & Oncol, Tubingen, Germany; [Neubauer, Andreas] Philipps Univ Marburg, Univ Hosp Giessen & Marburg, Marburg, Germany; [Ganser, Arnold] Hannover Med Sch, Hannen_US
dc.authoridGanser, Arnold/0000-0003-3510-4304
dc.authoridMohty, Mohamad/0000-0002-7264-808X
dc.identifier.pmid36698616en_US
dc.identifier.scopus2-s2.0-85147806304en_US
dc.identifier.wosWOS:000940863500001en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster